Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12701821 | 0.88 | ALDH1A1 (0.50) | ALDH1A1MAPTTSHRCYP3A4RECQL | |
| SCHEMBL4434688 | 0.86 | TSHR (0.53) | ALDH1A1MAPTTSHRCYP3A4RECQL | |
| SCHEMBL713941 | 0.85 | TSHR (0.54) | ALDH1A1MAPTTSHRCYP3A4KMT2A | |
| SCHEMBL31747006 | 0.85 | TSHR (0.54) | ALDH1A1MAPTTSHRCYP3A4KMT2A | |
| SCHEMBL17704660 | 0.85 | ALDH1A1 (0.58) | ALDH1A1MAPTTSHRCYP3A4RECQL | |
| SCHEMBL8295810 | 0.83 | ALDH1A1 (0.56) | ALDH1A1MAPTTSHRCYP3A4RECQL | |
| SCHEMBL28698370 | 0.83 | TSHR (0.49) | ALDH1A1MAPTTSHRCYP3A4RECQL | |
| SCHEMBL515466 | 0.82 | MAPT (0.54) | ALDH1A1MAPTTSHRCYP3A4TTR | |
| SCHEMBL13239654 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MAPTTSHRCYP3A4RECQL | |
| SCHEMBL20707091 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MAPTTSHRCYP3A4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486115-B1 | ELECTRORHEOLOGIC FLUID COMPRISING ORGANIC SUBSTANCES THAT CAN BE DOPED AND USE THEREOF | FRAUNHOFER GES FORSCHUNG (DE) | 2015-05-20 | — | — | EP | claimed |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| EP-4668303-A1 | CONDUCTIVE POLYMER DISPERSIONS FOR IMPROVED STABILITY PERFORMANCE OF CAPACITORS | Heraeus Epurio GmbH (DE) | 2025-12-24 | — | — | EP | disclosed |
| EP-4085059-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE HK LTD (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2023-04-20 | — | — | US | disclosed |
| EP-4085059-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | Accro Bioscience (HK) Limited (HK) | 2022-11-09 | — | — | EP | disclosed |
| US-11458590-B2 | Abrasive slurry regeneration method | Konica Minolta, Inc. (JP) | 2022-10-04 | — | — | US | disclosed |
| EP-3388195-B1 | METHOD FOR REGENERATING ABRASIVE SLURRY | KONICA MINOLTA INC (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-23 | — | — | US | disclosed |
| WO-2021138694-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2021-07-08 | — | — | WO | disclosed |
| EP-0791004-B1 | ACYLATED BENZYLGLYCOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PROD (US) | 1999-09-08 | — | — | EP | disclosed |
| US-5773420-A | Acylated benzylglycosides as inhibitors of smooth muscle cell proliferation | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0791004-A1 | ACYLATED BENZYLGLYCOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0791005-A1 | SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0791006-A2 | POLYANIONIC BENZYLGLYCOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| US-5565432-A | PREVENTING RESTENOSIS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996014324-A1 | SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-17 | — | — | WO | disclosed |
| WO-1996014325-A1 | ACYLATED BENZYLGLYCOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-17 | — | — | WO | disclosed |
| WO-1996014323-A1 | POLYANIONIC BENZYLGLYCOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-17 | — | — | WO | disclosed |
| US-5498775-A | Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | CASP6, CASP3, BAX | ALDH1A1 4013/4885MAPT 592/4885TSHR 591/4885 |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | BAX, PDCD1, PDCD4 | ALDH1A1 3695/4885MAPT 1983/4885TSHR 3786/4885 |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | ALDH1A1 4076/4885MAPT 3533/4885TSHR 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.